| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10036449 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS10050122 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS30085065 | HIV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007380 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007381 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20010779 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20035928 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20057329 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20021555 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20056904 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HRH1 |
|---|---|
| DrugBank ID | DB00967 |
| Drug Name | Desloratadine |
| Target ID | BE0000442 |
| UniProt ID | P35367 |
| Regulation Type | antagonist |
| PubMed IDs | 15564772; 7581058; 8174605; 11752352; 18336052; 17902729; 12642846; 18797058 |
| Citations | Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr: Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol. 2004 Dec;135(4):313-8. Epub 2004 Nov 24.@@Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J: [Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1995;63(5-6):281-5.@@Letari O, Miozzo A, Folco G, Belloni PA, Sala A, Rovati GE, Nicosia S: Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol. 1994 Feb 15;266(3):219-27.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30.@@DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83.@@Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22.@@Dhanya NB, Thasleem Z, Rai R, Srinivas CR: Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):361-3. |
| Groups | Approved; Investigational |
| Direct Classification | Benzocycloheptapyridines |
| SMILES | ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1 |
| Pathways | Desloratadine H1-Antihistamine Action |
| PharmGKB | PA164776964 |
| ChEMBL | CHEMBL1172 |
